Number of shares and votes in Active Biotech>

Number of shares and votes in Active Biotech

(Thomson Reuters ONE) - The number of shares and votes in Active Biotech has changed as aconsequence of the recently completed rights issue with pre-emptiverights for the shareholders.Today, the last trading day of the month, there are in total64,052,238 shares and votes in Active Biotech.Lund, June 30, 2009Active Biotech AB (publ)For further information, please contact:Hans Kolam, CFOTel: +46 (0)46 19 20 44E-mail: hans.kolam(at)activebiotech.comAbout Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Financial Instruments TradingAct to make the information in this press release public. Theinformation was submitted for publication at 08:30 am CET on June 30,2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.

Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 30.06.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 3007
Anzahl Zeichen: 0

contact information:
Town:

London

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 329 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Number of shares and votes in Active Biotech>"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech